Table 4.

Patient-Reported Outcome Scores for PRP Augmentation for Femoroacetabular Impingement Syndrome and Labral Surgery^a

Author (Year)	Outcome Score	Group	Pretreatment	Short-term FU	Midterm FU	Long-term FU	Extended FU
LaFrance (2015)29	mHHS	PRP	51.9	66.6	78.4	75.9	NR
		Normal saline	50.3	59.6	83.4	81.3
	HOS-ADL	PRP	59.1	68.4	79.6	84.1
		Normal saline	55.7	58.9	88.3	85.0
	HOS-SS	PRP	35.1	31.6	61.7	65.4
		Normal saline	29.2	20.2	75.6	75.2
	NAHS	PRP	54.9	66.3	81.3	82.0
		Normal saline	52.6	59.1	87.6	80.9
Rafols (2015)41	VAS	PRP	5.04	3.04	0.71	NR	NR
		No PRP	4.94	5.20	0.77
	mHHS	PRP	70.79	NR	94.80	NR	97.10
		No PRP	71.48		94.00		94.76
Redmond (2015)42	VAS	PRP	5.64	NR	2.62	NR	3.36
		BUP	5.44		2.58		2.52
	mHHS	PRP	62.77		82.09		78.58
		BUP	64.40		80.93		82.63
	HOS-ADL	PRP	64.49		81.63		79.77
		BUP	66.43		83.66		83.57
	HOS-SS	PRP	41.31		61.43		67.47
		BUP	43.52		61.83		69.08
	NAHS	PRP	58.02		76.62		78.34
		BUP	61.30		77.65		81.27

^aPosttreatment scores are divided into short-term (up to 2 months postop), midterm (3-6 months postop), long-term (12 months postop), and extended (24 months postop) follow-up time points. BUP, bupivacaine; FU, follow-up; HOS-ADL, Hip Outcome Score Activities of Daily Living subscale; HOS-SS, Hip Outcome Score Sport-Specific subscale; mHHS, modified Harris Hip Score; NAHS: Non-Arthritic Hip Score; NR, not reported; PRP, platelet-rich plasma; VAS, visual analog scale.